Company news

Capricor Therapeutics, Inc. news in 2019

Capricor Therapeutics, Inc.'s news releases, calls and decks from 2019, newest first.

View company

Capricor Therapeutics Announces Closing of $5.1 Million Offering Priced At-the-Market

December 18, 2019

Capricor Therapeutics Announces Pricing of $5.1 Million Offering Priced At-the-Market

December 16, 2019

Capricor Therapeutics Reports Third Quarter 2019 Financial Results and Provides Recent Corporate Update

November 6, 2019

Capricor Presents Additional Positive Data from Ongoing HOPE-2 Study of CAP-1002 in Duchenne Muscular Dystrophy at World Muscle Society: Data Demonstrates Improved PUL 2.0 Performance at 6 Months

October 6, 2019

Capricor to Present Interim Results from the HOPE-2 Trial in a Late Breaking Session of the World Muscle Society and Company to Host Conference Call Monday, October 7 at 5: 30 AM PT / 8: 30 AM ET

October 1, 2019

Capricor Therapeutics to Meet with FDA to Discuss CAP-1002 to Treat Duchenne Muscular Dystrophy

September 23, 2019

Capricor Therapeutics to Present Results from the HOPE-2 Trial of CAP-1002 in Duchenne Muscular Dystrophy in a Late Breaking Session of the World Muscle Society

September 16, 2019

Decks in 2019